DAFTAR PUSTAKA

1. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420–9.

2. Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Medicine (Baltimore). 2020;99(47):1–12.

3. Liu F, Li L, Xu M Da, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients withCOVID-19. J Clin Virol. 2020;127(4):1–5.

4. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467–74.

5. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: A meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Mol Psychiatry. 2016;21(5):642–9.

6. Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J. 2021;42(23):2280–3.

7. Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. EClinicalMedicine. 2020;23(4):1–7.

8. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856–62.

9. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(3):1–7.

10. Herold T, Jurinovic V, Arnreich C, Lipworth BJ. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J ALLERGY CUN Immunol. 2020;146(6):128–36.

11. Hammad MA, Sulaiman SAS, Aziz NA, Noor DAM. Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. J Res Med Sci. 2019;24(1):1–10.

12. KEMENKES. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID19). Kementrian Kesehatan Republik Indonesia. Jakarta; 2020. 1–214 p.

13. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020;16(5):1–24.

14. Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2020;0(0):1–10.

15. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32.

16. crusio WE, Dong H, Radeke HH, Rezaei N XJ. advances in experimental medicine and biology. tehran: springer; 2020. 1–61 p.

17. Tangianu F, Para O CF. COVID-19 in Clinical Practice Lessons Learned and Future Perspectives. 1st ed. Switzerland: springer; 2021. 10–2 p.

18. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 5. 5th ed. Pedoman Tatalaksana COVID-19. Jakarta; 2020. 36–7 p.

19. Monica M, Kurniawan A. Coronavirus Disease 2019 and Gastrointestinal Involvement: A Systematic Review. Medicinus. 2021;8(2):62–72.

20. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87–93.

21. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9(APR):1–11.

22. Mosquera-Sulbaran JA, Pedreañez A, Carrero Y, Callejas D. C-reactive protein as an effector molecule in Covid-19 pathogenesis. Rev Med Virol. 2021;31(6):1–8.

23. Ram M, Rao M, Gopal SD. Case Study C-Reactive Protein -A critical Review. IntJCurrMicrobiolAppSci. 2015;4(12):55–61.

24. Antonelli M, Kushner I. It's time to redefine inflammation. FASEB J. 2017;31(5):1787–91.

25. Landry A, Docherty P, Ouellette S, Cartier LJ. Causes and outcomes of markedly elevated C-reactive protein levels. Can Fam Physician. 2017;63(6):316–23.

26. Azar MM, Shin JJ, Kang I, Landry M. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. Expert Rev Mol Diagn. 2020;20(11):1087–97.

27. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;1(6):389–99.

28. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection. Vol. 136, Blood. 2020. 489–500 p.

29. Luan YY, Yin CH, Yao YM. Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections. Front Immunol. 2021;12(6):1–10.

30. Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med. 2020;252(1):73–84.

31. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.

32. Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J. 2021;42(23):2280–3.

33. Ngwa DN, Agrawal A. Structure-function relationships of C-reactive protein in bacterial infection. Front Immunol. 2019;10(4):1–7.

34. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):1–9.

35. Guan W jie, Liang W hua, Zhao Y, Liang H rui, Chen Z sheng, Li Y min, et al. Comorbidity and its on behalf of the China Medical Treatment Expert Group for COVimpact on 1590 patients with COVID-19 in China: a

nationwide analysis. Pneumologie. 2020;74(10):1–14.

36. Cremer S, Jakob C, Berkowitsch A, Borgmann S, Pilgram L, Tometten L, et al. Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clin Res Cardiol. 2021;110(7):1029–40.

37. Tessitore E, Carballo D, Poncet A, Perrin N, Follonier C, Assouline B, et al. Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. Open Hear. 2021;8(1):1–9.

38. Bochaton T, Lassus J, Paccalet A, Derimay F, Rioufol G, Prieur C, et al. Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients. PLoS One. 2021;16(1):1–13.

39. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020;50(3):587–95.

40. Zhang S, Zhang J, Wang C, Chen X, Zhao X, Jing H, et al. COVID-19 and ischemic stroke: Mechanisms of hypercoagulability (Review). Int J Mol Med. 2021;47(3):1–13.

41. McAlpine LS, Zubair AS, Maran I, Chojecka P, Lleva P, Jasne AS, et al. Ischemic stroke, inflammation, and endotheliopathy in covid-19 patients. Stroke. 2021;52(6):233–8.

42. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020;383(8):789–90.

43. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Front Immunol. 2020;11(3):1–22.

44. Ragy MM, Kamal NN. Linking senile dementia to type 2 diabetes: role of oxidative stress markers, C-reactive protein and tumor necrosis factor-α. Neurol Res. 2017;39(7):587–95.

45. Soliman A, Nair AP, Al Masalamani MS, De Sanctis V, Abu Khattab MA, Alsaud AE, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Biomed. 2020;91(3):1–9.

46. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–33.

47. Zafer MM, El-Mahallawy HA, Ashour HM. Severe COVID-19 and sepsis: Immune pathogenesis and laboratory markers. Microorganisms. 2021;9(1):1–13.

48. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–62.

49. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.

50. Leuzzi G, Galeone C, Taverna F, Suatoni P, Morelli D, Pastorino U. C-

reactive protein level predicts mortality in COPD: A systematic review and meta-analysis. Eur Respir Rev. 2017;26:1–14.

51. Obaidi AHA Al, Samarai AGM Al, Jawad AKY, Janabi JM Al. Association between C reactive protein and asthma. Turk Toraks Derg. 2010;11(3):98–104.

52. Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer. Med (United States). 2019;98(26):1–7.

53. Fortunato F, Martinelli D, Caputo S Lo, Santantonio T, Dattoli V, Lopalco PL, et al. Sex and gender differences in 19 : an Italian local register- • based study. 2021;1–7.

54. Štefan M, Chrdle A, Husa P, Beneš J, Dlouhý P. COVID-19: diagnosis and treatment. Klin Mikrobiol Infekc Lek. 2021;27(2):61–87.

55. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Heal - West Pacific. 2021;9:1–9.

56. Das SK. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). Indian J Clin Biochem. 2020;35(4):385–96.

57. Fresán U, Guevara M, Trobajo-Sanmartín C, Burgui C, Ezpeleta C, Castilla J. Hypertension and related comorbidities as potential risk factors for covid-19 hospitalization and severity: A prospective population-based cohort study. J Clin Med. 2021;10(6):1–12.

58. Bae SA, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: A systematic review and meta-analysis. Heart. 2021;107(5):373–80.

59. Mitra P, Suri S, Goyal T, Misra R, Singh K, Garg MK, et al. Association of Comorbidities with Coronavirus Disease 2019: A Review. Ann Natl Acad Med Sci. 2020;56(02):102–11.

60. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One. 2021;16(3 March):1–12.

61. Corrao S, Pinelli K, Vacca M, Raspanti M, Argano C. Type 2 Diabetes Mellitus and COVID-19: A Narrative Review. Front Endocrinol (Lausanne). 2021;12:1–10.

62. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Elsevier. 2020;(January):1–11.

63. Ciapponi A, Bardach A, Comandé D, Berrueta M, Argento FJ, Cairoli FR, et al. COVID-19 and pregnancy: An umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes. PLoS One. 2021;16:1–27.

64. Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Front Immunol. 2020;11:1–16.

65. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. COVID-19 and Cancer: Current Challenges and Perspectives. Elsevier. 2020;19–21.

66. Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. MBio. 2021;12(1):1–12.

67. Samiullah SM, Surekha A, Renuka Devi A, Nagajyothi B. Evaluation of the Secondary Bacterial Infections of Respiratory Tract in Covid 19 Patients. Indian J Med Microbiol. 2021;39:1–12.

68. Zhou F. Clinical Course And Risk Factors For Mortality Of Adult In Patients With COVID-19 In Wuhan, China: A Retrospective Cohort Study. J Med Study Res. 2020;3(1):1–10.

69. Bengoechea JA, Bamford CG. SARS - CoV- 2, bacterial co- infections, and AMR : the deadly trio in COVID - 19? EMBO Mol Med. 2020;12(7):10–3.

70. Xiaomin L, Wei Z, Xiaojie Y, Tangxi G, Benchao W, Hongxia X, et al. Prognostic value of C-reactive protein in patients with COVID-19 Xiaomin. Journals Gerontol Ser A Biol Sci Med Sci. 2018;(April):1–11.

71. Velavan TP, Meyer CG. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information. 2020;1–5.

72. Acar E, Demir A. The role of hemogram parameters and C- • reactive protein in predicting mortality in COVID- • 19 infection. 2021;1–11.

73. Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8(1):1–9.

74. Tang Y, Liang P, Chen J, Fu S, Liu B, Feng M, et al. The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population. Immun Ageing. 2018;15(1):1–8.

75. Kanmani S, Kwon M, Shin MK, Kim MK. Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study. Sci Rep. 2019;9(1):1–8.

76. Mei Z, Li H, Serdula MK, Flores-Ayala RC, Wang L, Liu JM, et al. C-reactive protein increases with gestational age during pregnancy among Chinese women. Am J Hum Biol. 2016;28(4):574–9.

77. Lentner J, Adams T, Knutson V, Zeien S, Abbas H, Moosavi R, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States. J Osteopath Med. 2021;121(12):869–73.

78. Devran Ö, Karakurt Z, Adigüzel N, Güngör G, Moçin ÖY, Balci MK, et al. C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit. Multidiscip Respir Med. 2012;7(6):1–6.

79. Villoteau A, Asfar M, Otekpo M, Loison J, Gautier J, Annweiler C. Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients. PLoS One. 2021;16(9):1–9.

80. Bannaga AS, Tabuso M, Farrugia A, Chandrapalan S, Somal K, Lim VK, et al. C-reactive protein and albumin association with mortality of hospitalised SARS-CoV-2 patients: A tertiary hospital experience. Clin Med J R Coll Physicians London. 2020;20(5):463–7.

81. Valerio L, Ferrazzi P, Sacco C, Ruf W, Kucher N, Konstantinides S V., et al. Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients. Thromb Haemost. 2021;121(1):98–101.

82. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856–62.

83. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. 2020;8925:1–5.

84. Tsivgoulis G, Tsivgoulis G, Katsanos AH, Ornello R, Sacco S. Ischemic Stroke Epidemiology during the COVID-19 Pandemic: Navigating Uncharted Waters with Changing Tides. Stroke. 2020;1924–6.